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Helicobacter pylori-related extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue is a paradigm for
malignancy arising in an inﬂammatory background. While the diagnosis of H. pylori gastritis is often straightforward, distinction
between severe gastritis and early lymphoma can be diﬃcult and requires careful assessment of clinical ﬁndings in addition
to histological features and immunohistochemical results. A number of cytogenetic abnormalities have been discovered in H.
pylori-related lymphomasand severalhaveclinicalimportance, related to the responsiveness oflymphomato H. pylori eradication
therapy, but routine molecular studies are not widely utilized. While molecular methods may be used in equivocal cases, a trial
of conservative therapy is warranted given the propensity for these lymphomas to regress with eradication of the organism. Once
therapy is initiated, care must be taken to avoid a premature assignment of disease refractoriness because complete response can
take several months to more than a year. Cases truly refractory to H. pylori eradication therapy may be treated with adjuvant
chemoradiation with a high response rate.
1.Introduction
Helicobacter pylori i sac o m m o np a t h o g e na n dt h em o s t
frequent cause of gastric and duodenal ulcers (Figure 1)
[1, 2]. This Gram-negative, curved bacillus was ﬁrst rec-
ognized as the cause of human disease by Marshall and
Warren in the 1980s and has since been classiﬁed as a class
I carcinogen, potentially leading to gastric adenocarcinoma
and, more commonly, extranodal marginal zone lymphoma
of mucosa-associated lymphoid tissue (MALT lymphoma)
[2–6]. Most H. pylori-related MALT lymphomas arise in the
stomach, but extragastric lymphomas may also be related
to the organism, particularly in the duodenum [7]. The
gastritis caused by H. pylori is morphologically distinctive,
with a band-like inﬁltrate of plasma cells and lymphocytes
in the superﬁcial gastric mucosa, typically in the antrum,
accompanied by active (neutrophilic) inﬂammation in the
mucus neck region of the mucosa, at the interface between
thefoveolaeandglands.WhileH.pylorigastritisismostoften
easily recognized, the dividing line between severe gastritis
and early MALT lymphoma is frequently indistinct [6, 7].
Several cytogenetic abnormalities have been described in
gastrointestinal (GI) MALT lymphoma, and inappropriate
activation of the NF-κB pathway is a common thread [8–11].
While molecular assays for these abnormalities are available,
guidelines for their routine use are not widely accepted,
and the vast majority of cases of gastric as well as many
extragastric, MALT lymphomas respond to conservative
therapy aimed at eradication of infection [8, 12–17]. Some
cytogenetic translocations seen in a subset of MALT lym-
phomas, however, are associated with resistance to antibiotic
therapy. The routine use ofmolecularassays in diagnosisand
prognosis of MALT lymphomas is controversial, and many
cases are negative for any known cytogenetic abnormality
[18–20].
This paper summarizes the current knowledge of cytoge-
netic abnormalities in GI MALT lymphoma, with particular
attention to H. pylori-related gastric lymphomas. Currently
available molecular testing methods are discussed, followed
by a practical approach to their use in diagnosis. Finally,
recommendations for disease followup are oﬀered, with
an emphasis on the utility of conservative therapy and2 Pathology Research International
avoidance of a premature determination of refractoriness to
H. pylori eradication therapy.
2.MALTLymphoma:A ReviewofConcepts
MALT lymphoma (Figure 2)i sal o w - g r a d eB - c e l ll y m -
phoma composed predominantly of small lymphocytes, ﬁrst
described around the same time as H. pylori by Isaacson
and Wright [21]. Morphologically, the lymphoma cells may
be centrocyte-like (with small nuclei and scant cytoplasm,
resembling follicle center cells) or monocytoid (with ample
pale cytoplasm and indented nuclei), often with admixed
centroblast-like cells (large cells that may have prominent
nucleoli) [6]. Monocytoid cells are fairly characteristic of
MALT lymphoma, butindividual cases are commonly a mix-
ture of the three cell types, with centroblast-like large cells
typically being individually scattered. Plasmacytic diﬀerenti-
ationiscommon,andsome casesare almostcompletelyplas-
macyticinappearance[6,22].Whileimmunohistochemistry
(IHC) is useful in diagnosis, there remains no speciﬁc IHC
marker for MALT lymphoma [7, 18].
MALT lymphoma accounts for about 8% of all B-cell
lymphomas and tends to occur in older individuals with a
nearlyequalsexdistribution[22].About85%ofallGIMALT
lymphomas occur in the stomach, and isolated involvement
of the small intestine is rare [7]. Conversely, about 25% of
gastric MALT lymphomas are accompanied by involvement
of other GI sites, and there is evidence that it is a truly
systemic disease [6, 18, 23]. The vast majority of GI MALT
lymphomas are thought to be related to H. pylori infection,
which is believed to lead to malignant transformation
via chronic antigenic stimulation resulting in the clonal
expansion of subpopulations of B cells [18, 24–27]. The
noninfected stomach is largely devoid of lymphoid tissue;
H. pylori gastritis owes its appearance to the acquisition
of a lymphoplasmacytic inﬁltrate in the gastric lamina
propria, which may or may not be accompanied by B-
cell nodules and even germinal centers [6, 7, 18]. This
type of tissue is termed “acquired MALT” to distinguish it
from “native MALT” of the type seen, for example, in the
distal ileum, where germinal centers make up the Peyer’s
patches.
Interestingly, while MALT lymphoma is a clonal B-
cell neoplasm, the process of lymphomagenesis is believed
to be driven by activated T cells [7, 27–29]. H. pylori
strains expressing the CagA gene have been associated with
signiﬁcant morbidity, and this gene may play a role in lym-
phomagenesis [30]. The transformation of H. pylori-related
MALTlymphoma todiﬀuselargeB-celllymphoma(DLBCL)
has been postulated, although the exact mechanism of such
a transformation remains obscure [6, 11, 18]. DLBCL is the
most common GI lymphoma overall and the presence of a
large cell component should be mentioned in the diagnosis
when itoccursin association with MALTlymphomas [7,22].
Sheets of large (centroblast-like) cells should prompt an
unequivocal diagnosis of DLBCL, even when a recognizable
low-grade MALT component is also present. Furthermore,
such a low-grade component should be mentioned with
Figure 1: Helicobacter pylori, the underlying cause of most cases
of gastric MALT lymphoma. The curved bacteria are seen in the
surface mucus layer of the gastric pits and have a characteristic,
curvilinear, “gull-wing” appearance (600x original magniﬁcation).
Figure 2: MALT lymphoma. The histomorphology in this case
closely resembles severe H. pylori gastritis. Note the inﬁltration
of the muscularis mucosae at the base of the mucosa (arrows).
The clinical information was crucial in this case, as diﬀusely
thickened gastric folds were seen endoscopically (400x original
magniﬁcation).
the diagnosis of DLBCL when present. The former diagnosis
of “high-grade MALT lymphoma” is no longer recognized
and should not be used.
3.CytogeneticAbnormalitiesin
GastrointestinalMALTLymphoma
3.1. t(11;18)(q21;q21) API2/MALT1. The t(11;18) transloca-
tioninvolvesthefusion oftheN-terminusofAPI2(apoptosisPathology Research International 3
inhibitor-2) on chromosome 11 and the C-terminus of
MALT1 (MALT lymphoma associated translocation) on
chromosome 18. It is the most common translocation found
in MALT lymphomas of the GI tract, involving up to
25% of gastric MALT lymphoma and 40%–60% of MALT
lymphoma occurring in the small intestine [31, 32].
The presence of this translocation correlates with resis-
tance to antibiotic therapy and MALT occurring without
concomitant chronic active H. pylori gastritis, although it
has been seen in speciﬁc strains of H. pylori infection
[32, 33]. Cases with this translocation are more likely to have
disseminated rather than stage I disease, butitis infrequently
associated with diﬀuse large B-cell lymphoma [34,35]. Some
evidence suggests that plasmacytic morphology may not be
seen in such cases [36].
Assays for the presence of t(11;18) are widely available.
Methods include ﬂuorescence in situ hybridization (FISH)
or reverse transcription polymerase chain reaction (RT-
PCR), both of which can be performed on fresh tissue or
archival formalin-ﬁxed paraﬃn-embedded tissue. FISH is
more sensitive in the rare cases that do not involve the
most common breakpoint. Dual color dual fusion FISH
has been in use for the past ten years utilizing metaphase
chromosomes or interphase nuclei [37]. In addition, break-
apart MALT1 FISH probes are available, relatively easily
interpreted in comparison to fusion probes, and may have
the advantage of being useful in detecting MALT1 rearrange-
ments in either t(11;18) or t(14;18) (see below) using one
assay. IHC for BCL10 protein will show nuclear expression
in many cases with the translocation; however, this is not
speciﬁc and can be seen in t(1;14)(p22;q32) in association
with the BCL10/IGH fusion [32]. The vast majority of cases
with t(11;18) will show weak cytoplasmic MALT1 protein
expression using IHC [38].
3.2. t(14;18)(q32;q21) IgH/MALT1. The t(14;18) transloca-
tion involves the immunoglobulin heavy chain gene (IgH)
on chromosome 14 and MALT1 on chromosome 18 which
activates the NF-κBp a t h w a y[ 39]. This translocation may
coexist with trisomies (3, 12,or18). While the breakpointon
chromosome18isinthesameregionasthatseeninfollicular
lymphoma, the gene involved is MALT1 rather than BCL2;
rare cases of MALT lymphoma have reportedly been asso-
ciated with the IgH-BCL2 fusion [40]. While IgH/MALT1 is
present in a large minority of MALT lymphomas, it occurs
more commonly in non-GI sites. It has been reported,
however, in unusual GI sites such as the liver [41].
Assays to detect t(14;18) include dual fusion FISH
and PCR. IHC for MALT1 and BCL10 is highly sensitive,
typically exhibiting strong, uniform cytoplasmic expression
[38]; however, neither of these immunostains is speciﬁc for
this translocation, as weak cytoplasmic staining for MALT1
and strong nuclear staining for BCL10 are characteristic of
t(11;18). As these immunostains can be expressed in other
translocations, they are not speciﬁc markers.
3.3. t(1;14)(p22;q32) BCL10/IGH. The t(1;14) translocation
juxtaposes the BCL10 gene on chromosome 1 with the IgH
gene on chromosome 14. A variant translocation involving
lambda light chain on chromosome 2 has also been reported
[42]. These translocations are present in a minority of
MALT lymphoma (1%–3%); however, it is important as
gastric MALT lymphoma with this translocation can also
demonstrate antibiotic resistance [43]. It has not been
reported in other non-Hodgkin lymphomas. As mentioned
previously, IHC for BCL10 shows strong nuclear expression.
MALT1 is weakly expressed in the cytoplasm [38].
3.4. t(3;14)(q27;q32) BCL6/IGH and Other BCL6 Rear-
rangements. BCL6 translocations are involved in a small
number of MALT lymphomas, approximately 1%-2% in
one large study [44]. The translocation can involve the
immunoglobulinheavychain, lightchains, orotherpartners.
Of relevance in GI cases, it has been reported in cases of
diﬀuse large B-cell lymphoma with concurrent MALT in the
stomach [45].
BCL6 rearrangements can be identiﬁed by FISH using
dual color break-apart probes. In a subset of BCL6 rear-
ranged cases, IHC for BCL6 protein will show nuclear
staining of the lymphocytes which can cause diagnostic
confusion with follicular lymphoma [44]. Only 25%–30%
of the cases with the translocation in this study showed
BCL6 expression by IHC. The number of cases is small, and
additional large studies are needed.
3.5. t(3;14)(p14.1;q32) FOXP1/IGH. This translocation can
be seen in diﬀuse large B-cell lymphoma and MALT
lymphomas (ocular, thyroid, and cutaneous) without the
t(11;18) [46]; it has not been commonly associated with
MALT lymphomas of the GI tract.
3.6. Trisomy 3 and 18. Chromosomal trisomies are com-
monly detected in gastrointestinal marginal zone lym-
phomas but are nonspeciﬁc. Trisomy 3q27 is the most
common chromosomal abnormality in gastrointestinal lym-
phomas. In one large series, it was present in 50%–
65% of low-grade MALT lymphomas from stomach and
small intestine [47]; however, other series showed a lower
prevalence [31, 48]. It occurs in both low-grade marginal
zone lymphomas and DLBCL and is more common in
patients with higher stage disease [49]. Trisomy 18 can be
seen independently or in association with trisomy 3 and has
also been correlated with more aggressive disease, especially
in gastrointestinal lymphomas classiﬁed as diﬀuse large B-
cell lymphoma [50]. Both trisomies can be detected using
FISH with chromosomal enumeration probes, and break-
apart probes for BCL6 and MALT1 may also potentially
identify these abnormalities.
4.Diagnosis ofMALTLymphoma and Use of
Molecular Assays:A PragmaticApproach
The distinction between severe H. pylori gastritis and early
MALT lymphoma is often diﬃcult and requires careful
assessment of clinical ﬁndings as well as histomorphology
and IHC. A carefully reasoned and evidence-based diagnosis4 Pathology Research International
of an incipient MALT lymphoma may not be clinically
helpful when the lack of endoscopic ﬁndings makes it
impossible for the gastroenterologist to ﬁnd an appropriate
site for rebiopsy to assess the eﬀectiveness of therapy.
Thus, discussion with clinical colleagues and a conscientious
search of the clinical and endoscopic record for lesions
including masses, malignant-appearing ulcers, and diﬀusely
thickened gastric folds are helpful in evaluating the patient
for malignancy. In reality, the vast majority of gastric MALT
lymphomas—possibly as many as80%ormore—will regress
in time with conservative H. pylori eradication therapy,
including cases that are organism negative by IHC [51].
Some evidence suggests that MALT lymphomas in locations
outside the stomach may also regress with conservative
therapy. As a result, erring on the side of diagnostic caution
in the setting of dubious clinical ﬁndings is prudent.
Morphological features helpful in the diagnosis of MALT
lymphoma include bona ﬁde epithelial and mucosal injury,
typiﬁed by the so-called “lymphoepithelial lesion”, a char-
acteristic but nonspeciﬁc inﬁltration of epithelial structures
by lymphoma cells (Figure 3)[ 6, 7, 52]. Care must be
taken to avoid overinterpretation of such lesions, however,
as they may also appear in benign settings including reactive
lymphoid inﬁltrates and in crypts adjacent to normal Peyer’s
patches. Reactive germinal centers, common in the deeper
mucosain H. pylori gastritis, may be colonizedby lymphoma
cells,withdestructionofthemantle zoneandtheappearance
of so-called “naked” follicles [6, 7]. In more extensive
cases, the lymphoma can create mucosal ulcers and can
inﬁltrate the muscularis mucosae, the submucosa, and even
the muscularis propria. Muscularis mucosae inﬁltration and
disruption can be a useful clue to the diagnosis in small
biopsy specimens. While no speciﬁc IHC marker is available,
an overabundance of B cells is present on CD20 stain, and
aberrant coexpression of CD43by neoplastic B-cells is found
in up to 50% of cases in large series [6, 53]. In cases with
extensive (or nearly complete) plasmacytic diﬀerentiation,
IHC for kappa and lambda light chains can be extremely
useful in highlighting a restricted plasma cell population, as
such cases can closely mimic the intense plasma cell inﬁltrate
of severe H. pylori gastritis. The standard application of
light chain IHC, however, is not particularly helpful for
determining the clonality of small lymphocytes, in our
experience.
Studiesofclonalitycanbeuseful in lymphomadiagnosis,
butroutineuseofmolecularstudiessuchasheavy-chaingene
rearrangement assays to aid in a determination of lympho-
cyteclonalityinMALT lymphoma isnot ourpractice. Clonal
populations have been demonstrated in nonneoplastic H.
pylori gastritis and, as noted earlier, equivocal cases are
probably best treated conservatively as most will respond
to H. pylori eradication [54, 55]. In addition, a signiﬁcant
number of MALT lymphomas may not exhibit detectable
clonal IgH rearrangements [54, 56]. Furthermore, biopsy
specimens are usually small and easily exhausted, putting the
slides cut for adequate morphological and IHC analysis at a
premium. Thus, the diﬀerential diagnosis of severe gastritis
and incipient lymphoma is best made based on a combi-
nation of clinical information, histomorphology, and IHC.
Figure 3: Lymphoepithelial lesions. This inﬁltration and destruc-
tion of the gastric gland epithelium by lymphocytes is a character-
istic, but not speciﬁc, feature of MALT lymphoma (400x original
magniﬁcation).
Whether pretreatment analysis of molecular cytogenetics to
determine the likelihood of treatment response is useful
remains a topic of debate, although some reports indicate
that it can be used in equivocal cases to help determine
malignancy [36]. Reported cytogenetic abnormalities in
gastric MALT lymphomas are summarized in Table 1.
Once the diagnosis of MALT lymphoma has been made
and H. pylori eradication therapy initiated, the deﬁnition of
treatment failure must be considered. While the majority
of cases will respond to conservative therapy, the timing of
rebiopsy for assessment of response is crucial in avoiding an
inappropriate judgment of failure. Complete resolution of
the lymphoid inﬁltrate typically takes several months, and
periods aslongastwo yearsto completeresolution havebeen
reported [14]. While it is typical practice in the setting of
colonic adenomas to rebiopsy for assessment of complete
polyp removal after a few weeks’ time to allow for mucosal
healing, at least eight to twelve weeks between initiation of
therapy and followup biopsy for MALT lymphoma is more
prudent. Certainly, an assessment of failure is inappropriate
before at least eight to twelve weeks have elapsed, as the
lymphomatousinﬁltratemay notlooksubstantivelydiﬀerent
in such a short time. Even at two to three months’ treatment
duration (some observers suggest as long as a year), only
a morphologically obvious worsening of the inﬁltrate or
endoscopically visible increase in mass or lesion size should
beconsideredalikelyfailure.Inaddition,molecularevidence
of clonality by IgH gene rearrangement studies may persist
for years after morphological remission is achieved, appar-
ently without aﬀecting patient outcome [14, 57]. Molecular
analysis for t(11;18)(q21;q21) may be used in unresponsive
cases, although the known association of this translocation
withrefractoriness toH.pylorieradicationtherapymaymake
such an assay unnecessary at this point in the disease course.
Furthermore, there have been reports of antibiotic responsePathology Research International 5
Table 1: Cytogenetic abnormalities in gastric MALT lymphomas, along with their reported frequencies, known clinical implications and
available assays for their detection.
Abnormality % Gastric MALT Clinical implications Available assay(s)
t(11;18)(q21;q21) Up to 25% Antibiotic resistance FISH; RT-PCR; BCL10 IHC
(nuclear)
t(14;18)(q32;q21) Up to 5% Unknown
FISH; PCR; MALT1 and
BCL10 IHC
(cytoplasmic/perinuclear)
t(1;14)(p22;q32) Rare Antibiotic resistance BCL10 IHC (nuclear)
t(3;14)(q27;q32) Rare
Reported in DLBCL
with concurrent
MALT
FISH (break-apart); BCL6
IHC (only 25%–30%)
Trisomies 5%–65%, depending
on series
3q27 most common;
associated with
high-stage disease
FISH
in cases with this translocation [51, 58]. Thus, further study
is needed to determine the utility of molecular assays in
determining prognosis and directing therapy for patients
refractory to conservative treatment [59].
Refractory cases may require more aggressive adjuvant
therapy, including systemic chemotherapy and/or radiother-
apy [12, 60]. MALT lymphomas have been found to be
very sensitive to such systemic treatment [61, 62]. Cases
with minimal residual mucosal disease, however, may be
best managed by watchful waiting [63, 64]. Rarely, but
particularly in cases that have transformed to DLBCL,
surgery may be necessary to deal with complications such
as intractable bleeding or perforation, and there is some
discussion about whether surgical intervention should be
reconsidered for primary therapy [65]. In addition to the
presence of certain translocations described earlier, other
factors associated with refractoriness to conservative therapy
are transmural inﬁltration and transformation to DLBCL. A
small number (around 10%) of cases will relapse, but this is
typically associated with H. pylori reinfection [60].
To summarize, while the diagnosis of gastric MALT
lymphoma and its deﬁnitive diﬀerentiation from severe H.
pylori gastritis can be diﬃcult and are not amenable to a
speciﬁc, algorithmic approach, our diagnostic methodology
involves several touchstones. First, the simple presence of
a lymphoplasmacytic inﬁltrate, with or without H. pylori
organisms, is insuﬃcientforadiagnosisofMALTlymphoma
and, indeed, is probably best regarded as H. pylori-type
gastritis and treated conservatively. We generally require
microscopic evidence of signiﬁcant mucosal disruption and
injury—ideally accompanied by macroscopic features such
as an endoscopically visible ulcer, mass, or thickened gastric
folds—to raise any suspicion of lymphoma. In this setting,
we perform an IHC panel that includes CD3, CD20, and
CD43 to conﬁrm an excess of CD20-postive B cells, possibly
with the addition of kappa and lambda light chain stains if
a signiﬁcant plasmacytic component is suspected. Aberrant
coexpression of CD43 by the B cells adds further evidential
weight to the diagnosis, but is only present in up to 50%
of cases. We rarely, if ever, utilize molecular assays for
either clonality or speciﬁc chromosomal abnormalities, as
biopsy tissue is generally sparse and the vast majority of
cases will respond to H. pylori eradication therapy. For
followup, we recommend rebiopsy after at least 12 weeks,
with the expectation that the inﬁltrate at that point may
n o tb em a r k e d l yb e t t e r ,b u ts h o u l da tl e a s tb en ow o r s e .W e
routinely compare follow-up biopsies to previous material
and, given the known propensity for MALT lymphoma
inﬁltrates to persist for several months to more than a year,
we assiduously avoid an assignment of treatment-refractory
status to a lymphoma unless it fails to appreciably improve
after several months of therapy or recognizably worsens
during therapy. For follow-up biopsies, we mention the
status of the inﬁltrate in our reports, either in the diagnostic
line or in a comment, such as “Stomach, biopsy: Residual
MALT lymphoma, signiﬁcantly improved from the prior
biopsy on [date]”.
5.Conclusion
Surgical pathologists commonly face the diagnosis of H.
pylori gastritis, and severecases can be diﬃcult to distinguish
from H. pylori-associated MALT lymphoma, particularly
in the absence of suspicious clinical features. Happily, the
large majority of such lymphoma cases respond to con-
servative antibiotic-based therapy for H. pylori eradication.
Several cytogenetic abnormalities, including chromosomal
translocations and trisomies, have been described in MALT
lymphoma, and two translocations [t(11;18)(q21;q21) and
t(1;14)(p22;q32)] are associated with resistance to conser-
vative treatment. The routine use of molecular studies,
includingthoseforclonalitysuchasIgH generearrangement,
in the diagnosis of MALT lymphoma is controversial,
however, and a trial of conservative therapy is probably the
best initial approach given the propensity for response to
such treatment. Careful assessment of response is crucial,
since lymphomas may take several months to more than
a year to exhibit a complete resolution of the malignant
lymphoid inﬁltrate. Thus, a premature declaration of treat-
ment refractoriness shouldbeavoidedinordertopreventthe
inappropriate use of more aggressive adjuvant therapy.6 Pathology Research International
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